Literature DB >> 19761515

Early use of probiotics is important therapy in infants with severe congenital anomaly.

Yutaka Kanamori1, Tadashi Iwanaka, Masahiko Sugiyama, Makoto Komura, Takuya Takahashi, Norikatsu Yuki, Masami Morotomi, Ryuichiro Tanaka.   

Abstract

BACKGROUND: Infants with severe congenital anomaly often need to undergo operation followed by antibiotic therapy. As a result they inevitably acquire abnormal intestinal microbiota, which cause severe infections such as necrotizing enterocolitis. Also, intestinal function deteriorates and their nutritional state is very poor. In order to prevent these situations probiotic therapy is proposed as an effective supporting treatment. Probiotic therapy were therefore applied to infants with severe congenital anomaly as early as possible to ascertain its efficacy.
METHODS: As probiotics, two bacteria were used: Bifidobacterium breve Yakult and Lactobacillus casei Shirota. Probiotic therapy was used in four infants with severe congenital anomaly as early as possible after surgery. Their intestinal microbiota and physical growth were followed through the treatment course.
RESULTS: Two patients suffered from meconium peritonitis with ileal atresia. One patient was born with complex anomalies (omphalocele, bladder exstrophy, myelomeningocele). The fourth patient suffered from complete urorectal septum malformation. The intestinal microbiota of these four patients was first induced to be probiotic dominant and finally changed to commensal anaerobe dominant that was similar to normal intestinal microbiota. Pathogenic bacteria were seldom detected. The patients' physical growth was excellent despite short bowel and pulmonary hypoplasia.
CONCLUSION: Probiotic therapy was effective in inducing probiotic dominant intestinal microbiota and normal intestinal microbiota in infants with severe congenital anomalies. As a result their intestinal absorptive functions were activated and severe infections were completely prevented. All of the infants grew well despite their physical disadvantages.

Entities:  

Mesh:

Year:  2009        PMID: 19761515     DOI: 10.1111/j.1442-200X.2009.02963.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  5 in total

1.  Intestinal microbiota in neonates requiring urgent surgery: assessing the role of probiotics using fecal DNA sequencing.

Authors:  Hiroshi Murakami; Yumi Shimomura; Mitsuharu Matsumoto; Geoffrey J Lane; Atsuyuki Yamataka; Manabu Okawada
Journal:  Pediatr Surg Int       Date:  2015-10-29       Impact factor: 1.827

Review 2.  Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges.

Authors:  Per T Sangild; Denise M Ney; David L Sigalet; Andreas Vegge; Douglas Burrin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-10-23       Impact factor: 4.052

Review 3.  Therapeutic Microbiology: The Role of Bifidobacterium breve as Food Supplement for the Prevention/Treatment of Paediatric Diseases.

Authors:  Nicole Bozzi Cionci; Loredana Baffoni; Francesca Gaggìa; Diana Di Gioia
Journal:  Nutrients       Date:  2018-11-10       Impact factor: 5.717

4.  Colonisation of the proximal intestinal remnant in newborn infants with enterostomy: a longitudinal study protocol.

Authors:  Inês Barreiros Mota; Cláudia Marques; Ana Faria; Maria Teresa Neto; Gonçalo Cordeiro-Ferreira; Daniel Virella; Ana Pita; Luís Pereira-da-Silva; Conceição Calhau
Journal:  BMJ Open       Date:  2019-11-24       Impact factor: 2.692

Review 5.  Recent Development of Probiotic Bifidobacteria for Treating Human Diseases.

Authors:  Jun Chen; Xinyi Chen; Chun Loong Ho
Journal:  Front Bioeng Biotechnol       Date:  2021-12-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.